Endosomal gene expression: a new indicator for prostate cancer patient prognosis?
AuthorsJohnson, Ian R D
Parkinson-Lawrence, Emma J
Spillane, Cathy D
Watson, William R
Butler, Lisa M
O'Leary, John J
Brooks, Doug A
MeSHAdaptor Proteins, Signal Transducing
Adaptor Proteins, Vesicular Transport
Cell Cycle Proteins
Endosomal Sorting Complexes Required for Transport
Gene Expression Profiling
Neoplasm Recurrence, Local
Prostatic Intraepithelial Neoplasia
Real-Time Polymerase Chain Reaction
Reverse Transcriptase Polymerase Chain Reaction
Vesicular Transport Proteins
rab5 GTP-Binding Proteins
MetadataShow full item record
CitationEndosomal gene expression: a new indicator for prostate cancer patient prognosis? 2015, 6 (35):37919-29 Oncotarget
AbstractProstate cancer continues to be a major cause of morbidity and mortality in men, but a method for accurate prognosis in these patients is yet to be developed. The recent discovery of altered endosomal biogenesis in prostate cancer has identified a fundamental change in the cell biology of this cancer, which holds great promise for the identification of novel biomarkers that can predict disease outcomes. Here we have identified significantly altered expression of endosomal genes in prostate cancer compared to non-malignant tissue in mRNA microarrays and confirmed these findings by qRT-PCR on fresh-frozen tissue. Importantly, we identified endosomal gene expression patterns that were predictive of patient outcomes. Two endosomal tri-gene signatures were identified from a previously published microarray cohort and had a significant capacity to stratify patient outcomes. The expression of APPL1, RAB5A, EEA1, PDCD6IP, NOX4 and SORT1 were altered in malignant patient tissue, when compared to indolent and normal prostate tissue. These findings support the initiation of a case-control study using larger cohorts of prostate tissue, with documented patient outcomes, to determine if different combinations of these new biomarkers can accurately predict disease status and clinical progression in prostate cancer patients.
- Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
- Authors: Debiais-Delpech C, Godet J, Pedretti N, Bernard FX, Irani J, Cathelineau X, Cussenot O, Fromont G
- Issue date: 2014 May
- Altered endosome biogenesis in prostate cancer has biomarker potential.
- Authors: Johnson IR, Parkinson-Lawrence EJ, Shandala T, Weigert R, Butler LM, Brooks DA
- Issue date: 2014 Dec
- Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells.
- Authors: Le Magnen C, Bubendorf L, Ruiz C, Zlobec I, Bachmann A, Heberer M, Spagnoli GC, Wyler S, Mengus C
- Issue date: 2013 Mar
- WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence.
- Authors: Lin B, Utleg AG, Gravdal K, White JT, Halvorsen OJ, Lu W, True LD, Vessella R, Lange PH, Nelson PS, Hood L, Kalland KH, Akslen LA
- Issue date: 2008 Mar 1
- Asporin is a stromally expressed marker associated with prostate cancer progression.
- Authors: Rochette A, Boufaied N, Scarlata E, Hamel L, Brimo F, Whitaker HC, Ramos-Montoya A, Neal DE, Dragomir A, Aprikian A, Chevalier S, Thomson AA
- Issue date: 2017 Mar 14